Want to see IMRN full AI Analyst Report?
IMRN Stock Chart & Stats
$0.82
-$0.03(-1.20%)
At close: 4:00 PM EST
$0.82
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous CloseN/A
Volume5.19K
Average Volume (3M)75.95K
Market Cap
$9.70M
Enterprise Value-$1.44
Total Cash (Recent Filing)$9.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding8,071,202
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$6.43M
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity ratio reflects a conservative capital structure that reduces interest burdens and financial distress risk. For a small biotech, low leverage preserves optionality to fund R&D or pursue partnerships, improving financing flexibility over the next several months.
High Gross MarginsSustained gross margins near 65% indicate strong product-level economics from colostrum-derived formulations. If operating expenses are managed, these margins provide a clear path to structural profitability as commercial scale increases or if production efficiencies are realized.
Commercial Product & DistributionAn existing commercial product and retail/pharmacy distribution channels supply recurring revenue and market presence while the pipeline matures. This real-world commercialization capability supports partnerships, revenue continuity, and validation of the oral antibody platform long-term.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow signal ongoing cash burn that reduces runway and increases reliance on external funding. Over a 2-6 month horizon this elevates dilution and refinancing risk and can constrain investment in clinical programs or commercial expansion.
Persistently Negative ProfitabilitySustained negative net, EBIT and EBITDA margins indicate the business is not generating operating profits. This limits internal funding for R&D and commercialization, makes long-term viability dependent on successful pipeline outcomes or continued external capital raises.
Declining RevenueA recent top-line decline suggests market or execution challenges for core products. Falling revenue reduces scale economies and increases pressure on margins and cash flow, raising the urgency for either product growth, new market traction, or additional financing to sustain operations.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $9.70M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 39 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Feb 25, 2026. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.192.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,071,202 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went up 17.103%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors